Expanding Platform Technologies Including Glycoscience-Based DDS Technology
First written in FY2019. 2 of 3 entries say "Restated". Latest entry: FY2020-Q3.
No other company in this theme has enough history to compare yet.
- FY2020-Q3RestatedAnnual report
「<Main technologies held by the company> a. Drug discovery through modification, processing and biological activity b. Applications to drug delivery systems (DDS) c. Use of platform technologies and next-generation GAG drug discovery approaches」
The company continues to pursue measures to strengthen its technology base using modification, processing and biological activity, DDS, platform technologies and next-generation GAG drug discovery, based on carbohydrate science. - FY2020-Q2RestatedAnnual report
「<Main technologies held by the company> a. Drug discovery through modification, processing and biological activity b. Applications to drug delivery systems (DDS) c. Use of platform technologies and next-generation GAG drug discovery approaches」
The medium-term management plan specified measures to strengthen core technologies based on carbohydrate science, using modification, processing and biological activity, DDS, platform technologies and next-generation GAG drug discovery. - FY2019First statedAnnual report
「In addition to expanding core technologies, including drug delivery system (DDS) technologies based on carbohydrate science, we will promote an open innovation strategy to improve the efficiency of research and development.」
The company identified for the first time the expansion of core technologies, including carbohydrate science-based DDS technologies, as a new initiative to improve R&D efficiency.